Deborah Weitzman
Known title: CEO, Pharmaceutical SegmentCIK: 0001942639
Associated companies
Transaction History
| CAH | ▼ Sell | Open Market | 6,665 | $1.6M | 8/18/2026 | View on chart |
| CAH | ▼ Sell | Open Market | 408 | $97K | 8/18/2026 | View on chart |
| CAH | ▼ Sell | Open Market | 281 | $67K | 8/18/2026 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 29,759 | $7.0M | 8/15/2026 | View on chart |
| CAH | ▲ Buy | Grant | 7,314 | $0 | 8/15/2026 | View on chart |
| CAH | ▲ Buy | Grant | 54,823 | $0 | 8/4/2026 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 551 | $117K | 12/1/2025 | View on chart |
| CAH | ▼ Sell | Open Market | 21,367 | $3.2M | 8/20/2025 | View on chart |
| CAH | ▲ Buy | Grant | 10,694 | $0 | 8/15/2025 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 24,128 | $3.6M | 8/15/2025 | View on chart |
| CAH | ▲ Buy | Grant | 39,100 | $0 | 8/12/2025 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 632 | $77K | 12/2/2024 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 2,341 | $253K | 8/16/2024 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 9,918 | $1.1M | 8/15/2024 | View on chart |
| CAH | ▲ Buy | Grant | 13,530 | $0 | 8/15/2024 | View on chart |
| CAH | ▲ Buy | Grant | 13,926 | $0 | 8/13/2024 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 638 | $68K | 12/1/2023 | View on chart |
| CAH | ▲ Buy | Option Exercise | 5,990 | $505K | 11/27/2023 | View on chart |
| CAH | ▲ Buy | Option Exercise | 6,279 | $522K | 11/27/2023 | View on chart |
| CAH | ▲ Buy | Option Exercise | 15,373 | $1.0M | 11/27/2023 | View on chart |
| CAH | ▼ Sell | Open Market | 36,642 | $3.9M | 11/27/2023 | View on chart |
| CAH | ▲ Buy | Option Exercise | 6,712 | $479K | 8/28/2023 | View on chart |
| CAH | ▼ Sell | Open Market | 6,712 | $603K | 8/28/2023 | View on chart |
| CAH | ▲ Buy | Grant | 15,487 | $0 | 8/16/2023 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 10,966 | $1.0M | 8/15/2023 | View on chart |
| CAH | ▲ Buy | Grant | 12,760 | $0 | 8/7/2023 | View on chart |
| CAH | ▼ Sell | Tax Withholding | 380 | $30K | 12/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cardinal Health Hits Record Highs as Sector Strength Continues
Cardinal Health's stock has reached record highs, outperforming the broader market as the healthcare sector shows strong momentum. In corporate news, Senior Vice President Shane Abeyratne has joined the Customer Experience Advisory Board of Level AI. Meanwhile, market observers are looking ahead to the company's upcoming Q1 2027 earnings report and its position as a defensive option in the current economic environment.
Cardinal Health Hits Record Highs as Sector Strength Continues. Cardinal Health's stock has reached record highs, outperforming the broader market as the healthcare sector shows strong momentum. In corporate news, Senior Vice President Shane Abeyratne has joined the Customer Experience Advisory Board of Level AI. Meanwhile, market observers are looking ahead to the company's upcoming Q1 2027 earnings report and its position as a defensive option in the current economic environment.